The New Launch Playbook

Launching innovative medicines can no longer follow conventional precedent. The old formula -- U.S. first, Europe second, rest of world later -- is increasingly misaligned with the realities of today’s health policy, pricing, and market access environment.

And for some assets, following the traditional launch sequence may actually destroy long-term value.

Not because the science is flawed.

But because the strategy is.